Efficacy and Safety of CKD-828 to Stage 2 Hypertension

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 103 participants.

Also called NCT01634295

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 103 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01634295
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01634295. Randomized; triple masking; primary purpose treatment. Start 2012-07 (registry gives no type); primary completion 2013-05 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of CKD-828 to Stage 2 Hypertension
Condition
Hypertension
Intervention (Drug)
CKD-828 2.5/40mg
Intervention (Drug)
CKD-828 5/40mg
Intervention (Drug)
CKD-828 5/80mg
Intervention (Drug)
S-amlodipine 2.5mg
Intervention (Drug)
S-amlodipine 5mg
Lead sponsor
Chong Kun Dang Pharmaceutical (class: industry)

Record details

Record id
cardio:ct-nct01634295
Content hash
4b0ea45628ab7ee12d761c2aa1f92636f24804fcc5cc30e096d6478b0031db93